Author name: David Thomas

David Thomas is Vice President of Industry Research at the Biotechnology Innovation Organization (BIO). David covers investment, R&D and alliance deal trends as well as regulatory statistics that impact policy initiatives in Washington. Prior to joining BIO, David spent over a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. David is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.

As biotech market seeks rebound, economic and political environments are key

BIO's View, Editors' Choice, Health, Latest News

If you are a regular reader of Bio.News, you likely know that the past two years have been difficult for the biotech market. Investor …

As biotech market seeks rebound, economic and political environments are key Read More »

Author name: David Thomas

Start typing and press enter to search